Related Experiment Video
Updated: Jul 13, 2026
07:32
Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
[Mercury and Alzheimer's disease]
J Mutter1, J Naumann, R Schneider
1Institut für Umweltmedizin und Krankenhaushygiene, Universitätsklinik Freiburg (Franz Daschner), Breidacher Strasse 115b, 79106 Freiburg i. Brsg. joachim.mutter@uniklinik-freiburg.de
Fortschritte Der Neurologie-Psychiatrie
|July 14, 2007
Summary
Higher mercury levels in the brain are linked to Alzheimer's disease (AD). While not definitively proven as the sole cause, inorganic mercury from sources like dental amalgam appears to play a significant role in AD development, potentially exacerbated by other metals.
Area of Science:
- Neuroscience
- Toxicology
- Environmental Health
Context:
- Elevated mercury concentrations are observed in brain and blood of Alzheimer's disease (AD) patients.
- Inorganic mercury exposure, particularly from dental amalgam, is associated with higher mercury levels in brain tissues.
- Other metals can exacerbate mercury's toxic effects, suggesting complex interactions in AD etiology.
Purpose:
- To investigate the role of mercury, specifically inorganic mercury from dental amalgam, in the development of Alzheimer's disease.
- To explore how other metals and genetic factors like apolipoprotein E4 influence mercury's toxicity and AD risk.
- To evaluate the potential of metal chelation therapies in treating Alzheimer's disease.
Summary:
- Low levels of inorganic mercury can induce AD-typical neuronal damage in vitro and in animal models.
- Dental amalgam is a significant source of mercury vapor, leading to higher brain mercury levels in individuals with amalgam fillings.
- Apolipoprotein E4 (APOE4) carriers may have an increased AD risk due to impaired heavy metal binding, suggesting a role in mercury's neurotoxicity.
- Chelation therapy targeting synergistic toxic metals, including mercury, shows preliminary success in Alzheimer's treatment.
Impact:
- Findings suggest inorganic mercury may be a decisive factor in Alzheimer's disease etiology, acting alongside other co-factors.
- This research supports the investigation of environmental and genetic factors in AD pathogenesis.
- Highlights the potential therapeutic benefit of targeting metal accumulation in the brain for AD treatment.
More Related Videos
07:07Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze
Published on: October 29, 2019
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.